

Myocarditis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/M9A4CE113FBDEN.html>

Date: March 2022

Pages: 45

Price: US\$ 2,000.00 (Single User License)

ID: M9A4CE113FBDEN

Abstracts

Myocarditis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myocarditis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Myocarditis (Cardiovascular) pipeline landscape.

Myocarditis is inflammation of the heart muscle. Myocarditis is an uncommon disorder that is usually caused by viral, bacterial, or fungal infections that reach the heart. Symptoms include chest pain, rapid or abnormal heartbeat, shortness of breath, at rest or during physical activity, fluid retention with swelling of legs, ankles and feet and fatigue. Treatment includes antibiotics, anti-inflammatory medicines to reduce swelling and diuretics to remove excess water from the body.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myocarditis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Myocarditis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the

therapeutics, its complete research and development history and latest news and press releases.

The Myocarditis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocarditis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Myocarditis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Myocarditis (Cardiovascular).

The pipeline guide reviews pipeline therapeutics for Myocarditis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Myocarditis

(Cardiovascular) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Myocarditis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Myocarditis (Cardiovascular)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Myocarditis (Cardiovascular).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Myocarditis (Cardiovascular) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Myocarditis - Overview
- Myocarditis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Myocarditis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Myocarditis - Companies Involved in Therapeutics Development
- Cantargia AB
- Cardiol Therapeutics Inc
- Dynomics Inc
- Evotec SE
- Inflamma Therapeutics LLC
- Swedish Orphan Biovitrum AB
- Worg Pharmaceuticals Hangzhou Co Ltd
- Myocarditis - Drug Profiles
- anakinra - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ATX-MYO - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CAN-10 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- cannabidiol 1 - Drug Profile
- Product Description

Mechanism Of Action

History of Events

coxsackievirus B (hexavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

DYN-502 - Drug Profile

Product Description

Mechanism Of Action

IFT-100 - Drug Profile

Product Description

Mechanism Of Action

Recombinant Peptides for Myocardial Infarction and Myocarditis - Drug Profile

Product Description

Mechanism Of Action

Myocarditis - Dormant Projects

Myocarditis - Product Development Milestones

Featured News & Press Releases

Dec 13, 2021: Cantargia reports positive results for CAN10 antibody in preclinical systemic sclerosis model

Nov 08, 2021: Cantargia reports progress in manufacturing process development and provides update on clinical trial preparations for CAN10

Oct 25, 2021: Cardiol Therapeutics receives Health Canada approval for phase II clinical trial of CardiolRx for acute myocarditis

Aug 24, 2021: Cardiol Therapeutics receives FDA clearance of investigational new drug (IND) application for phase II clinical trial of CardiolRx for acute myocarditis

May 10, 2021: Cantargia presents new preclinical data showing unique improvement of heart function in myocarditis using antibody CAN10

Apr 28, 2021: Cardiol Therapeutics announces first patient enrolled in LANCER, a Phase II/III outcomes trial in high-risk patients hospitalized with COVID-19

Apr 26, 2021: Cantargia presents new preclinical data on antibody CAN10 at IMMUNOLOGY2021

Apr 12, 2021: Cardiol Therapeutics announces topline results from phase I single and multiple ascending dose clinical trial of CardiolRx

Mar 19, 2021: Cantargia reports positive preclinical safety and efficacy results in the CAN10 project

Dec 22, 2020: Cardiol Therapeutics announces completion of phase I clinical study of CardiolRx

Nov 27, 2020: BioInvent signs monoclonal antibody manufacturing deal with Cantargia

Aug 26, 2020: Cardiol Therapeutics initiates Health Canada approved Phase 1 clinical

study of CardiolRx

Apr 07, 2020: Cantargia provides update on development project CAN10

Apr 05, 2020: Cardiol Therapeutics receives Health Canada approval for phase 1 study of its pharmaceutically produced cannabidiol (CBD) formulation

Apr 01, 2020: Cardiol Therapeutics announces study results confirm the cardioprotective role of its pharmaceutical cannabidiol formulation in a model of heart failure

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Myocarditis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Myocarditis - Pipeline by Cantargia AB, 2022
Myocarditis - Pipeline by Cardiol Therapeutics Inc, 2022
Myocarditis - Pipeline by Dynomics Inc, 2022
Myocarditis - Pipeline by Evotec SE, 2022
Myocarditis - Pipeline by Inflamma Therapeutics LLC, 2022
Myocarditis - Pipeline by Swedish Orphan Biovitrum AB, 2022
Myocarditis - Pipeline by Worg Pharmaceuticals Hangzhou Co Ltd, 2022
Myocarditis - Dormant Projects, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Myocarditis, 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Myocarditis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/M9A4CE113FBDEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M9A4CE113FBDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

